会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Synaptogyrin homolog
    • 突触体蛋白同源物
    • US5854413A
    • 1998-12-29
    • US700637
    • 1996-04-30
    • Phillip R. HawkinsSusan G. StuartLynn E. Murry
    • Phillip R. HawkinsSusan G. StuartLynn E. Murry
    • A61K38/00C07K14/47C12P21/02C07H21/04C12N5/10C12Q1/68
    • C07K14/47A61K38/00
    • The present invention provides a polynucleotide (snpg) initially isolated from a colon cDNA library which identifies and encodes a novel human synaptogyrin homolog (SNPG). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding SNPG. The invention also provides for the use of SNPG in the membrane of a vesicle containing a chemical or biological therapeutic composition for the treatment of disease, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the abnormal or excess expression of SNPG. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of snpg, or anti-SNPG antibodies which specifically bind to the polypeptide, SNPG.
    • 本发明提供了最初从结肠cDNA文库中分离的多核苷酸(snpg),其鉴定并编码新的人类突触蛋白同源物(SNPG)。 本发明提供了包含编码SNPG的核酸序列的遗传工程表达载体和宿主细胞。 本发明还提供了SNPG在含有用于治疗疾病的化学或生物治疗组合物的囊泡的膜中的用途,以及用于治疗相关的病症或疾病的反义分子,抗体,拮抗剂或抑制剂的治疗用途 与SNPG的异常或过量表达。 本发明还描述了使用包含与多肽,其片段或其互补序列的基因组序列或snpg的转录物或特异性结合多肽SNPG的抗SNPG抗体杂交的诊断组合物的诊断测定法。
    • 8. 发明授权
    • Method of detecting human phospholipase inhibitor
    • 检测人磷脂酶抑制剂的方法
    • US5948626A
    • 1999-09-07
    • US153751
    • 1998-09-15
    • Phillip R. HawkinsLynn E. Murry
    • Phillip R. HawkinsLynn E. Murry
    • G01N33/53A61K31/7088A61K38/00A61K45/00A61K48/00A61P25/28C07K14/47C07K16/18C12N1/15C12N1/19C12N1/21C12N5/10C12N9/99C12N15/09C12Q1/68
    • C12Q1/6876C07K14/4703A61K38/00C12Q2600/158
    • The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of gipl, or anti-GIPL antibodies which specifically bind to the polypeptide, GIPL.
    • 本发明提供了一种多核苷酸(gipl),其部分序列最初从THP-1 cDNA文库中分离,并鉴定并编码新的人磷脂酶抑制剂(GIPL)。 本发明提供了包含编码GIPL的核酸序列的遗传工程表达载体和宿主细胞。 本发明还提供了纯化GIPL及其激动剂在药物组合物中用于治疗与异常或过量磷脂酶活性相关的疾病的用途。 另外,本发明提供了用于预防妊娠或治疗阿尔茨海默病的药物组合物中的GIP1或GIPL抑制剂的反义分子的用途。 本发明还描述了利用包含多核苷酸,其片段或其互补物的诊断组合物的诊断测定法,其与gipl的基因组序列或转录物或特异性结合多肽GIPL的抗GIPL抗体杂交。
    • 9. 发明授权
    • Human phospholipase inhibitor protein
    • 人类磷脂酶抑制蛋白
    • US5811520A
    • 1998-09-22
    • US919706
    • 1997-08-29
    • Phillip R. HawkinsLynn E. Murry
    • Phillip R. HawkinsLynn E. Murry
    • G01N33/53A61K31/7088A61K38/00A61K45/00A61K48/00A61P25/28C07K14/47C07K16/18C12N1/15C12N1/19C12N1/21C12N5/10C12N9/99C12N15/09C12Q1/68C07K1/00
    • C12Q1/6876C07K14/4703A61K38/00C12Q2600/158
    • The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of gipl, or anti-GIPL antibodies which specifically bind to the polypeptide, GIPL.
    • 本发明提供了一种多核苷酸(gipl),其部分序列最初从THP-1 cDNA文库中分离,并鉴定并编码新的人磷脂酶抑制剂(GIPL)。 本发明提供了包含编码GIPL的核酸序列的遗传工程表达载体和宿主细胞。 本发明还提供了纯化GIPL及其激动剂在药物组合物中用于治疗与异常或过量磷脂酶活性相关的疾病的用途。 另外,本发明提供了用于预防妊娠或治疗阿尔茨海默病的药物组合物中的GIP1或GIPL抑制剂的反义分子的用途。 本发明还描述了利用包含多核苷酸,其片段或其互补物的诊断组合物的诊断测定法,其与gipl的基因组序列或转录物或特异性结合多肽GIPL的抗GIPL抗体杂交。